N/A N=161 GIOTRIF in First Line Therapy of Advanced NSCLC With EGFR-mutations
Carcinoma, Non-Small-Cell Lung
Primary: Progression Free Survival (PFS) Rate After 12 Months — 50.24 Percent probability of PFS
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=30 Transcutaneous Peripheral Neuromodulation for Neurogenic Bladder
Urinary Bladder, Neurogenic
Primary: Patient Perception of Bladder Condition Questionnaire — 3; 3 units on a scale
Phase 1 N=54 Glucophage Extended Release (GXR) China Bioequivalence Study (Nantong - Darmstadt)
Healthy
Primary: Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Sampling Time (AUC 0-t) of Metformin — 3740; 3780; 5500; 5540 nanogram*hour per milliliter…
Phase 1 N=36 Evaluation of the Vasoconstriction Properties of MC2-01 Cream
Vasoconstriction
Primary: Comparison of the Vasoconstriction Potential (Skin Blanching Effect) of the MC2-01 Cream With Active Comparators and Vehicle — 1.66; 3.05; 2.45; 1.92 score on a scale
Phase 4 N=239 Comparative Study of ELLIPTA Dry Powder Inhaler (DPI) Versus DISKUS DPI Used With HandiHaler DPI in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Pulmonary Disease, Chronic Obstructive
Primary: Percentage of Participants With Zero Errors After 28 Days of Inhaler Use in Each Treatment Phase (Primary Estimand: Hypothetical) — 96; 87 Percentage of participants…
Phase 1 N=16 A Study to Compare the Pharmacokinetics (PK) of GSK2982772 Following Administration of Different Modified Release (MR) Formulations in Capsule and MR Tablet Formulations Relative to an Immediate Release (IR) Tablet Formulation and to Check the PK of MR Formulation in Capsule Following Repeat Doses
Autoimmune Diseases
Primary: Area Under the Curve From Time Zero to Infinity (AUC[0-inf]) of GSK2982772 in IR Formulation: Part A — 6.305 Hours*microgram per milliliter
Phase 2 N=14 High and Low Dose Carbidopa Treatment of Parkinson's Disease
Parkinson's Disease
Primary: Area Under the Curve (AUC) of Tapping Speed — 141; 141; 145; 201 (taps/min)*(hours)
N/A N=67 Contralaterally Controlled FES of Arm & Hand for Subacute Stroke Rehabilitation
Stroke · Hemiparesis · Hemiplegia
Primary: Change in Box and Block Test (BBT) Score at 6 Months Post-Treatment — 13.5; 12.6; 9.6 blocks
Phase 4 N=121 Dexmedetomidine and IV Acetaminophen for the Prevention of Postoperative Delirium Following Cardiac Surgery
Delirium
Primary: Incidence of Delirium — 2; 4; 8; 9 Participants
Phase 2 N=22 Fecal Microbiota Transplantation for the Treatment of Obesity
Obesity
Primary: Adverse Event Frequency — 11; 11; 1; 0 Participants
N/A N=125 Safety and Efficacy Study of Transcatheter Closure of Ostium Secundum ASDs
Atrial Septal Defect
Primary: Number of Subjects With 6-Month Closure Success — 112 Participants — p=<0.0001
Phase 2 N=23 A Study to Assess the Effect of Intravenous Dose of (aMBMC) to Subjects With Non-ischemic Heart Failure
Non-Ischemic Heart Failure
Primary: Safety Will be Evaluated by Number of AE — 38; 35; 1; 1 number of events
Phase 2 N=113 Study of MK-3475 in Patients With Microsatellite Unstable (MSI) Tumors (Cohorts A, B and C)
MSI Positive Colorectal Cancer · MSI Negative Colorectal Cancer · MSI Positive Non-Colorectal Cancers
Primary: Immune-related Progression Free Survival (irPFS) at 20 Weeks in MSI Positive and Negative Colorectal Adenocarcinoma Participants Using Immune Related Response Criteria…
Phase 2 N=29 Erlotinib Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome · Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11 · Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11
Primary: Participants With a Response — 3 Participants
N/A N=14 Intraoperative Folate Targeted Fluorescence in Renal Cell Carcinoma
Renal Cell Carcinoma
Primary: Number of Participants With Presence of Fluorescence of cT1 RCC in Partial Nephrectomy Specimens — 10 Participants